Clinical Report: Alcon Introduces Voyager DSLT at AGS

Overview

Alcon's Voyager Direct Selective Laser Trabeculoplasty (DSLT) is now available in the U.S., offering a non-contact, automated approach to glaucoma treatment. Clinical data indicate noninferiority to traditional SLT at 6 months, with sustained efficacy and safety observed up to 12 months.

Background

The introduction of the Voyager DSLT addresses the growing need for effective glaucoma treatments as laser trabeculoplasty becomes a primary therapy for open-angle glaucoma. This innovative device eliminates the need for gonioscopy, enhancing patient comfort and clinical efficiency. As glaucoma management evolves, the integration of automated technologies like Voyager DSLT is crucial for improving patient outcomes.

Data Highlights

The Voyager DSLT has demonstrated noninferiority to traditional SLT at 6 months and excellent efficacy and safety out to 12 months.

Key Findings

• Voyager DSLT is the first automated, non-contact laser for glaucoma treatment.
• The device automates targeting and delivery, eliminating the need for a gonioscopic lens.
• Clinical data support its use as a first-line treatment for open-angle glaucoma.
• Integration of Voyager DSLT into clinical practice has resulted in positive experiences for both providers and patients.
• SLT-first strategies have shown reduced need for glaucoma surgery and slower visual-field progression.

Clinical Implications

The Voyager DSLT represents a significant advancement in glaucoma treatment, streamlining the procedure and enhancing patient comfort. Clinicians should consider incorporating this technology as a first-line treatment option to improve patient management and outcomes.

Conclusion

The launch of Alcon's Voyager DSLT marks a pivotal development in glaucoma care, promising to enhance the efficiency and effectiveness of laser trabeculoplasty. Its automated features may lead to broader access and improved patient experiences in glaucoma treatment.

References

1. Ophthalmology Management, 2025 -- Alcon's Voyager DSLT Now Available in United States
2. Glaucoma Physician, 2026 -- One Year After DSLT Launch
3. Glaucoma Physician, 2025 -- Voyager DSLT Enhances First-Line Glaucoma Care
4. Ophthalmology Management, 2025 -- Quick Hits
5. FDA, 2023 -- Voyager DSLT Device Information
6. NICE, 2022 -- Update information | Glaucoma: diagnosis and management
7. Randomized Noninferiority Trial, 2025 -- Direct Selective Laser Trabeculoplasty in Open-Angle Glaucoma
8. https://www.accessdata.fda.gov/cdrh_docs/pdf23/K230722.pdf
9. Update information | Glaucoma: diagnosis and management | Guidance | NICE
10. Randomized Noninferiority Trial of Direct Selective Laser Trabeculoplasty in Open-Angle Glaucoma and Ocular Hypertension